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Abstract 
Background: Peroxisome proliferator activated receptor gamma (PPARG ) belongs to the nuclear receptor superfam‑
ily functioning as transcription factors to regulate cellular differentiation, development and metabolism. Moreover, it 
has been implicated in the regulation of lipid metabolism, as well as the maturation of monocytes/macrophages and 
the control of inflammatory reactions. The aim of this study was to evaluate the relationship between the Pro12Ala 
(rs1808212) PPARG gene polymorphism on immune molecular and cellular components in mothers and their off‑
spring participating in the PREOBE study.
Methods: DNA from maternal venous blood samples at 24, 34 and 40 gestational weeks, plus cord blood samples 
was extracted. Pro12Ala PPARG polymorphism genotyping was performed, and immune system markers were ana‑
lyzed by flow cytometry.
Results: Study findings revealed no effect of rs1808212 PPARG genotypes on innate immune parameters in mothers 
and their offspring; however, CD4 + /CD8 + ratio were decreased at 24 and 34 weeks in pregnant women carrying the 
CG (Pro12Ala) rs1808212 polymorphism, (p = 0,012 and p = 0,030; respectively). Only CD19 levels in peripheral blood 
were significantly higher at delivery in pregnant women carrying the CC (Pro12Pro) genotype (p ≤ 0.001). Moreover, 
there were statistically significant differences in leukocytes and neutrophils maternal levels at 34 weeks of gestation, 
being lower in carriers of Pro12Ala genotype (p = 0.028 and p = 0.031, respectively).
Conclusions: Results suggest that Pro12Ala PPARG polymorphism may have an effect on some cell and immune 
parameters in pregnant women during pregnancy and at time of delivery. However, newborn innate immune system 
does not seems to be influenced by PPARG Pro12Ala polymorphism in cord blood.
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Background
The immune system is our first line of defense against 
microbial infection. It is composed of leukocytes that 
secrete various immune molecules such as cytokines, 
chemokines, immunoglobulins, and complement pro-
teins in order to eliminate pathogens as well as mediate 
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cell-to-cell communication. A successful pregnancy 
requires a robust, dynamic and responsive immune sys-
tem. Immune modulation and tolerance induction are 
required at the beginning of the pregnancy to allow 
implantation, but a successful pregnancy also depends 
on a responsive immune system that can protect both 
the mother and the fetus against environmental insults 
when necessary [1]. Indeed, for a successful pregnancy 
outcome, the maternal immune system should have 
reinforced networks that can recognize danger signals, 
appropriately eliminate them and promote repair if 
needed. In addition to the maternal immune system, the 
fetal–placental unit has an actively developing immune 
system that can further modify the maternal immune 
response and how the maternal immune system reacts 
to the environment. As such, the immunological milieu 
during pregnancy is unique, modulated and dynamic, 
and definitely not suppressed [2].
Peroxisome proliferator activated receptors (PPARs) 
family belong to the nuclear receptor superfamily that 
functions as transcription factors to regulate cellular dif-
ferentiation, development and various metabolic pro-
cesses [3], especially lipid and glucose homeostasis [4]. 
To date, three PPARs have been identified: alpha (PPARA 
), delta (PPARD) and gamma (PPARG ). PPARG is highly 
expressed by adipocytes, skeletal muscles, liver and 
kidney, and to a lesser extent in colon and the immune 
cells–macrophages. PPARG gene is located on chromo-
some 3, contains 9 exons and expands more than 100 kb. 
A missense mutation resulting in an alanine substitu-
tion for proline at codon 12 (Pro12Ala) of the PPARG 
gene (rs1801282) is located close to the  NH2-terminal 
region of the protein, in the ligand independent activa-
tion domain, and has been found to modulate PPARG 
transcriptional activity. A reduced transcriptional activity 
of the PPARG gene as a result of Pro to Ala aminoacid 
substitution has been demonstrated [5]. Multiple diverse 
mechanisms converge on the activation function domain 
to regulate the transcriptional activity, and insulin sensi-
tizing potential, of PPARG [6]. Activation of PPAR sign-
aling pathways lead to an effect in lipid synthesis and 
oxidation, glucose uptake, inflammation, and expres-
sion of immunoregulatory genes. PPARG has a role in 
the maintenance of regulatory T cell numbers [7], as 
well as maturation of monocytes/macrophages and con-
trol of inflammatory reactions [3, 8, 9]. Differentiation 
and activation of these immune cells are linked to this 
nuclear hormone receptor [10, 11]. PPARG is expressed 
in various immune system cell types; both the innate and 
the adaptive immune system are strongly influenced by 
PPAR activation triggering macrophages and other leu-
kocyte populations, such as lymphocytes and dendritic 
cells [12].
Obesity is a metabolic disease that results in a chronic 
low-grade inflammation status, characterized by high 
levels of inflammatory mediators, such as C-reactive pro-
tein, interleukin (IL) 6, and TNF [13]. Once considered 
a high-income country problem, overweight and obesity 
are now on the rise in low- and middle-income coun-
tries, particularly in urban settings [14]. Excess weight/
adiposity is associated with several co-morbidities [15]. 
High rates of obesity in women of childbearing age [16, 
17] has made obesity the most common medical prob-
lem in pregnancy. A high body mass index (BMI) enter-
ing pregnancy and excess weight gain during pregnancy 
can exacerbate the natural inflammatory state associated 
with pregnancy resulting in detrimental health outcomes 
for the mother [18, 19], such as gestational diabetes, 
pre-eclampsia and delivery of macrosomic infants [20]. 
Furthermore, children born to women who enter preg-
nancy in an obesogenic state are at higher risk for sev-
eral adverse long-term health outcomes in comparison 
to children born to lean mothers [21]; maternal obesity 
is associated with increased incidence of cardiovascu-
lar disease, asthma, and diabetes in the offspring, thus, 
maternal obesity likely disrupts normal development and 
maturation of the offspring’s immune system in utero 
[13]. Obesity is a multifactorial condition, influenced by 
genes, lifestyle and environmental factors. Approximately 
40–70% of variation in obesity is attributed to genetic 
factors [22, 23]. While much of this genetic etiology 
remains unidentified, numerous studies have identified 
loci that are associated with in the general population. 
SNPs in FTO gene have been found significantly associ-
ated with pre-pregnancy obesity and body mass index in 
pregnant women [24]. Moreover, relationship between 
gene polymorphisms in PPARG [25] and overweight and 
obesity have also been reported. Recently, a direct effect 
on the weight gain during pregnancy has been reported 
associated to modified transcriptional activity of PPARG 
gene [26].
The main objective of this study is to examine the pos-
sible influence of PPARG Pro12Ala (rs1808212) polymor-
phism in pregnant women and their offspring on some 




Subjects participated in a Spanish prospective, observa-
tional, longitudinal study: “Study of Maternal Nutrition 
and Genetics on the Foetal Adiposity Programming”, 
PREOBE study (retrospectively registered at ClinicalTri-
als.gov; Identifier: NCT01634464). Briefly, healthy preg-
nant women with singleton pregnancies and age between 
18 and 45 were assessed for eligibility between 12 and 
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20 weeks’ gestation, as previously described [27, 28]; 145 
pregnant women and their offspring were eligible for the 
present study, although only 137 mothers were geno-
typed and analyzed, due to non-Spanish background of 
some of them, or having more than 1 child enrolled in the 
study, thus avoiding bias. Maternal age, pre-conceptional 
BMI, presence of gestational diabetes mellitus (GDM), 
smoking and alcohol habits, gestational age at delivery, 
gestational weight gain (GWG), mode of delivery, parity, 
placental weight, neonatal anthropometry (birth weight, 
birth length, and head circumference) and newborn sex 
was recorded.
All experimental procedures were approved by the 
Ethics Committees of the Universidad de Granada, and 
Mother-Infant and San Cecilio University Hospitals of 
Granada, Spain, and performed in line with the Declara-
tion of Helsinki II Principles. Written informed consent 
was obtained from all participant women prior to enroll-
ment in the study.
Pro12Ala (rs1808212) PPARG polymorphism genotyping.
Genomic DNA was obtained from blood leukocytes—at 
24, 34 weeks and at delivery—and venous umbilical cord 
blood, using phenol chloroform extraction protocol, and 
quantified by 0.8% agarose gel electrophoresis. Geno-
typing was performed using TaqMan™ SNP Genotyping 
Assay C_1129864_10 (Applied Biosystems, Foster City, 
CA, USA) on an ABI PRISM 7900HT Sequence Detec-
tion System according to manufacturers’ instruction kit 
and manual (Applied Biosystems, Foster City, CA, USA).
Cells blood count‑differential and lymphocyte phenotype
White blood cell (WBC) profiles were determined with 
an automatic haematology analyzer (ADVIA 2120 S 
Healthcare, Spain). For lymphocyte subsets analysis, 
blood aliquots were taken into 1.0  ml plastic tubes and 
diluted 1:1 with Cyto-Chex® (Streck Cell Preservative™ 
CE). Briefly, blood aliquots were incubated with mono-
clonal antibodies (BD Biosciences, San José, CA, USA), 
to differentially label  CD45+ (the pan-leukocyte marker), 
 CD3+ (T mature cells),  CD4+ (T helper cells),  CD8+ (T 
cytotoxic cells),  CD19+ (B cells), and  CD16+56+ (Natu-
ral Killer (NK) cells) for 30 min at room temperature. Red 
blood cells were lysed with lysing solution (Becton Dick-
inson), washed in phosphate buffered saline and resus-
pended. Lymphocytes were gated by forward and side 
scatter and pan-leukocyte marker expression (CD45) and 
by four-staining procedure (CD3-FITC/CD16 + 56-PE/
CD45-PerCP/CD19-APC and CD3-FITC/CD8-PE/
CD45-PerCP/CD4-APC) BD Pharmigen™ fluorochrome 
conjugated and analysed by flow cytometry (FACScan 
Plus Dual Laser, Becton Dickinson, Sunnyvale, CA, USA).
Serum samples were used for quantification of IL-6, 
IL-10, and TNF. A high sensitivity multiple analyte com-
mercial kit (HSCYTO-60-SK, Millipore, USA) was used 
with xMAP technology from Luminex® Corporation. 
Minimum detectable concentration was 0.10  pg/mL for 
IL-6, 0.15 pg/mL for IL-10 and 0.05 pg/mL for TNF. Low 
and high concentration quality controls were ran in the 
assay.
Statistical analysis
All statistical analyses were performed using SPSS v22.0 
statistical software package for Windows (IBM SPSS Inc., 
Chicago, IL, USA). To assess the data for normality, a 
Shapiro–Wilk test was performed. Descriptive statistics 
were mean and standard deviation (SD) for normal vari-
ables, and percentages for categorical ones. Comparison 
between rs1801282 PPARG genotypes using U Mann–
Whitney test for non-parametric distribution or Stu-
dent T test assuming equal variances with Levene test, 
were performed. Statistical significance level was set at 
p < 0.05.
All genotype data were checked for deviation from 
Hardy–Weinberg equilibrium (HWE) using http://ihg.
gsf.de/cgi-bin/hw/hwa1.pl.
Results
General characteristics of pregnant mothers participating 
in the current study are presented in Table 1. There were 
no statistically significant differences (p > 0.05) in demo-
graphic characteristics or pregnancy parameters (ges-
tational age, GWG, gestational diabetes development, 
placenta weight) and presence of Pro12Pro or Pro12Ala 
genotypes in mothers. As shown in Table  1, there were 
no maternal subjects presenting the GG genotype; allele 
frequencies were 93.07% C and 6.93% G, and rs1801282 
genotype distribution was in HWE (p = 0.38). The Ala12 
allele frequency in our population was comparable to 
previous studies in Spanish [29] and other Caucasian 
populations (5.9–21.6%) [30, 31].
Considering babies born to mothers of the study, there 
were no statistically significant differences in length 
(50.49 ± 2.13 vs. 50.10 ± 2.66, p > 0.05) or cephalic perim-
eter (34.58 ± 1.43 vs. 34.50 ± 1.54, p > 0.05) between those 
who were born to mothers carrying CC or CG genotypes, 
respectively. Regarding newborn weight, babies whose 
mothers carried CG genotype were heavier than those 
born to mothers carrying CC genotype (3329.66 ± 422.12 
vs. 3531.05 ± 481.25), although statistical significance was 
marginal (p = 0.061).
Concerning immunological parameters, comparison 
between Pro12Ala/CG vs. Pro12Pro/CC mothers’ geno-
type was done at different gestational weeks (Table  2). 
In general, data show an increase in levels of some of the 
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immune cells analyzed, such as leukocytes, neutrophils 
and monocytes, and decrease in levels of others (eosin-
ophils lymphocytes, and large unstained cells (LUC) 
percentage) along gestation. Furthermore, levels of lym-
phocyte cells antigen positive to cluster of differentiation 
3, 4, 8 and 19 (CD3, CD4, CD8 and CD19) seem to be 
decreased along pregnancy. No changes in levels of baso-
phils or NK cells have been noted in our study cohort. All 
determined biological parameters which were reported 
in our study, were normal values according to clinical ref-
erence values.
About the effect of PPARG rs1801282 genotypes on 
levels of immune cells [including total leukocytes, granu-
locytes (neutrophils, eosinophils and basophils), agranu-
locytes (monocytes, lymphocytes) and LUC%], in general 
there was no effect on those levels by PPARG Pro12Ala 
SNP distribution (p > 0.05), except at 34 weeks of gesta-
tion where statistically significant differences were found 
in leukocytes and neutrophils levels, being lower in car-
riers of Pro12Ala genotype (p = 0.028 and p = 0.031, 
respectively).
On the other hand, statistically significant differences 
were revealed in B-lymphocyte (CD19) counts and 
CD4/CD8 ratio between mothers carrying the CC and 
the CG genotypes: results show significant changes in 
CD19 cells at delivery (p < 0.001) and marginally signifi-
cant at 24 and 34 weeks of pregnancy. Conversely, CD4/
CD8 ratio varied significantly at 24 and 34 weeks of preg-
nancy (p = 0.012 and p = 0.030, respectively) between 
mothers with different genotypes, and also at delivery, 
although not reaching statistical significance in this last 
case. In these weeks of pregnancy (24 and 34) and at 
delivery, CD19 levels and CD4/CD8 ratio were increased 
in homozygous mothers compared against heterozygous 
mothers (Table  2). Finally, levels of cytokines such as 
TNF, IL-6 and IL-10 seem to be increased by the end of 
pregnancy; although no statistically significant effect of 
PPARG rs1801282 genotypes on levels of those cytokines 
were observed in our cohort (Table  2). Other immune 
molecules such as CD3, CD4 and CD8 were not found to 
be influenced by the genotypes in mothers during preg-
nancy and at delivery in our study.
Regarding babies born to mothers participating in 
the study, genotype frequencies were: 80 (89.89%) 
CC, 8 (8.99%) CG and 1 (1.12%) GG; allele frequencies 
were: 93.85% C and 6.15% G, and no deviation from 
Table 1 Maternal characteristics of study participants based on PPARG Pro12Ala (rs1801282) genotypes
Results are expressed as mean ± standard deviation, unless otherwise stated. Bold: P‑value < 0.05. HDL high density lipoproteins, LDL low density lipoproteins
Characteristics Pro12Pro (CC) (n:118) Pro12Ala (CG) (n:19) p
Maternal age (years) 31.54 ± 4.94 31.58 ± 4.46 0.976
Pre‑conceptional BMI (kg/m2) 26.93 ± 5.32 26.17 ± 5.39 0.565
Cultural level Primary/secondary (%) 60.17 57.89 0.851
University (%) 39.83 42.11
Family civil status Single (%) 4.24 0 0.361
Married/living with partner (%) 95.76 100
Diabetes (%) 30.51 26.32 0.711
Smoking during pregnancy (%) 15.79 11.11 0.607
Alcohol consumption during pregnancy (%) 5.22 5.56 0.952
Gestational age (week) 39.58 ± 1.23 39.68 ± 1.16 0.737
Weight gain during pregnancy (kg) 10.42 ± 7.20 9.01 ± 6.88 0.455
Mode of delivery Eutocic (%) 57.29 76.47 0.195
Dystocic (%) 17.70 17.65
C‑section (%) 25 5.88
Parity (%) 0 58.12 36.84 0.084
 ≥ 1 41.88 63.16
Placental weight 513.73 ± 126.77 482.35 ± 108.49 0.338
Newborn sex Boy/girl (%) 47.86/52.14 63.16/36.84 0.216
Glucose (mg/dl) 92.59 ± 32.61 90.50 ± 26.74 0.809
HbA1c (%) 4.86 ± 0.52 4.65 ± 0.42 0.135
Total cholesterol (mg/dl) 245.76 ± 49.73 253.13 ± 44.10 0.579
Triglycerides (mg/dl) 223.17 ± 80.71 238.06 ± 54.72 0.480
HDL‑cholesterol (mg/dl) 68.67 ± 18.33 72.38 ± 13.12 0.441
LDL‑cholesterol (mg/dl) 134.19 ± 41.07 133.13 ± 34.53 0.922
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Hardy–Weinberg equilibrium was detected (p = 0.15). 
Due to low frequency of minor homozygotes in the 
newborns, subsequent statistical analyses were done 
comparing CG + GG vs. CC. No statistically significant 
variation (p > 0.05) has been found in cord blood lev-
els of immune cells or cytokines between babies who 
carry CC major homozygous genotype and carriers of 
G (CG + GG) (Table  3). Levels of some granulocytes 
(eosinophils and basophils) and agranulocytes (mono-
cytes, lymphocytes), as well as the lymphocyte subsets 
CD3, CD4, CD8 and CD19 and CD4/CD8 ratio, are 
slightly increased compared to mothers at week 40 of 
pregnancy. On the contrary, neutrophils and LUC% 
decreased compared to mothers at time of delivery. 
Nevertheless, results obtained for newborn cord blood 
are in normal range according to clinical reference 
values.
Discussion
The main goal of the current study was to determine if 
rs1808212 PPARG polymorphism could be associated 
with immune cell and cytokine levels in mothers during 
gestation and in newborn cord blood. Our results suggest 
that during pregnancy, the majority of immune compo-
nents are not altered in Ala12 PPARG carrier mothers 
with respect to Pro12Pro subjects. However, CD19 mol-
ecules seem to vary slightly at second and third trimester 
of pregnancy and at time of delivery, although not reach-
ing statistically significant differences. B-lymphocyte 
antigen CD19 is a clinical biomarker linked to the lym-
phocyte B development, with relevance during early life. 
CD19 is a transmembrane protein which acts as an adap-
tor protein to recruit cytoplasmic signaling proteins to 
the membrane. Moreover, CD19 is critically involved in 
establishing intrinsic B cell signaling thresholds through 
Table 2 Immunological parameters in mothers according to rs1808212 PPARG genotypes along pregnancy
Results are expressed as mean (95% confidence interval). Bold: P‑value < 0.05. NK natural killer cells, LUC large unstained cells, IL interleukin
Immunological 
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modulating both B cell receptor dependent and inde-
pendent signaling. It plays roles in the antigen-independ-
ent development, as well as the immunoglobulin-induced 
activation of B cells. CD19 is thus critical for the body to 
mount an optimal immune response [32].
Results also suggest that CD4/CD8 ratio may be influ-
enced by PPARG Pro12Ala polymorphism during preg-
nancy, as there are statistically significant differences in 
mothers’ carriers of CC vs. carriers of CG genotypes in 
weeks 24 and 34, although not at 40 weeks. CD4 helper/
inducer cells and CD8 cytotoxic/suppressor cells are T 
lymphocytes phenotypes, characterized by distinct sur-
face markers and functions that mostly reside in lymph 
nodes but also circulate in the blood. CD4/CD8 ratios 
between 1.5 and 2.5 are generally considered normal; 
however, a wide heterogeneity exists because sex, age, 
ethnicity, genetics, exposures, and infections may all 
impact the ratio. A low or inverted CD4/CD8 ratio is an 
immune risk phenotype and is associated with altered 
immune function, immune senescence, and chronic 
inflammation [33]. Thus, the mothers with the non-prev-
alent genotype present a borderline normal ratio. None-
theless, despite statistically significant results obtained 
in the current study, values obtained in the CC and GC 
genotypes at the different times of the study overlap, so 
the differences may not be biologically significant.
Nuclear receptor PPARG has a major role in transcrip-
tional regulation of genes involved in various physiologic 
processes of clinical significance, such as developmen-
tal, metabolic and anti-inflammatory processes. PPARG 
plays a pivotal role in adipogenesis, fatty acid uptake, 
lipid storage and systemic energy homeostasis, as 
well as in the control of inflammation [34]. PPARG is 
expressed in blood cells and induced during macrophage 
differentiation [35]. It enhances macrophage lipid uptake 
and has anti-inflammatory effects [36], which are closely 
linked with its anti-diabetic effects [37]. PPARG is 
expressed in B lymphocytes [38] and T lymphocytes [39].
PPARG has anti-inflammatory properties and its 
ligands have been demonstrated to suppress production 
of monocyte/macrophages inflammatory cytokines such 
as TNF, IL-6, and IL-1β through inhibiting the activity 
of transcription factors such as nuclear factor κB, acti-
vator protein-1, and signal transducers and activators 
of transcription [10, 40, 41]. No statistically significant 
differences in levels of TNF, IL-6, and IL-10 cytokines 
in mother carriers of CG compared to those carrying 
CC genotype have been found at any time of pregnancy 
studied.
PPARG Ala12 allele has been related to increased 
long-term weight gain [42], and also with a reduction in 
type 2 diabetes risk [30]. In our study, mothers who car-
ried CG genotype were less prone to the development 
of diabetes during pregnancy against those who carried 
CC (26.32% vs. 30.51%), although not reaching statisti-
cal significance, it has been reported that subjects car-
rying Pro allele have increased diabetes risk [40, 43–45]. 
Other study reported that gestational diabetes mellitus 
is associated with increased leukocyte PPARG expres-
sion (46), which could explain the slight effects of PPARG 
polymorphism on lymphocytes subsets observed in our 
study. In this regard, as subject number involved in the 
current study is limited, replication in a larger popula-
tion is needed since reduced transcriptional activity of 
the PPARG gene result of Pro to Ala aminoacid substi-
tution has been demonstrated [5]. Results from a large 
scale meta-analysis shown that PPARG (rs1801282) was 
significantly associated with increased/decreased risk of 
Table 3 Immunological parameters in newborn cord blood according to rs1801282 PPARG genotype
Results are expressed as mean (95% confidence interval). NK natural killer cells, LUC large unstained cells.
Immunological parameters Pro12Pro (CC) n = 79 Pro12Ala (CG + GG) n = 9 p
Leukocytes  (103/µl) 13.84 (12.72–14.96) 13.95 (9.30–18.60) 0.95
Neutrophils  (103/µl) 7.41 (6.57–8.26) 6.94 (3.08–10.80) 0.73
Monocytes  (103/µl) 1.06 (0.94–1.18) 1.05 (0.64–1.45) 0.94
Eosinophils  (103/µl) 0.47 (0.41–0.53) 0.48 (0.16–0.80) 0.90
Basophils  (103/µl) 0.20 (0.17–0.24) 0.21 (0.11–0.31) 0.92
Lymphocytes  (103/µl) 4.40 (3.99–4.82) 5.07 (3.56–6.58) 0.32
CD3  (103/µl) 2.46 (2.21–2.71) 2.89 (1.79–3.98) 0.27
CD4  (103/µl) 1.65 (1.47–1.83) 2.11 (1.32–2.90) 0.11
CD8  (103/µl) 0.66 (0.55–0.77) 0.67 (0.35–0.98) 0.95
CD19  (103/µl) 0.57 (0.45–0.68) 0.62 (0.26–0.97) 0.77
CD4/CD8 2.86 (2.57–3.16) 3.44 (2.31–4.57) 0.21
NK  (103/µl) 0.88 (0.71–1.06) 1.17 (0.58–1.76) 0.29
LUC (%) 0.31 (0.26–0.36) 0.27 (0.14–0.39) 0.60
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GDM in Asian population, mostly from China, but not in 
Caucasian population [47].
Birth weight is slightly higher in the offspring of het-
erozygous mothers compared to homozygous pregnant 
women. However, no differences in newborn weight 
were found when comparing newborns CC carriers vs. 
CG + GG, as described above. These results are in line 
with a study in a large German cohort including mother/
child pairs showing that PPARG Pro12Ala polymorphism 
is not relevant for intrauterine growth, although effects 
developed later in life depending on predisposition or 
environmental factors could not be discarded [48]. How-
ever, it is opposed to another study in 208 Finnish sub-
jects in which they conclude that Ala12 allele of PPARG 
gene is associated with high weight and ponderal index 
at birth [49]. Since PPARG is involved in glucose and 
lipid metabolism, it could be considered as an impor-
tant molecular factor participating in these metabolic 
pathways during pregnancy. Indeed, decreased PPARG 
mRNA and protein levels have been observed in subcu-
taneous adipose tissue from obese gestational diabetic 
women, suggesting that this change might be part of the 
molecular mechanism to accelerate fat catabolism and 
thereby ensure fetal nutrition in late gestation [50].
Some limitations in the present study should be noted, 
as the sample size is relatively low, although sample char-
acteristics are quite homogeneous: all the mother–child 
pairs where from Spanish origin and no statistically sig-
nificant differences were found among groups depend-
ing on rs1808212 genotype distribution in clinical or 
demographic characteristics. No data is available about 
PPARG expression in our study population. Moreover, 
blood counts and cytokine levels data were not available 
at the beginning of the pregnancy. Thus, the study results 
should be taken with caution, and should be replicated in 
a larger population. Given the pivotal role that PPARG 
plays in lipid storage, systemic energy homeostasis and 
in the control of inflammation as well, more research is 
warranted in this field.
Conclusions
In summary, results suggest that PPARG Pro12Ala poly-
morphism might be one of the factors that would deter-
mine higher CD19 cells during pregnancy in homozygous 
PPARG rs1808212 SNP mothers, especially at delivery, 
compared to heterozygous participants. Additionally, 
CD4/CD8 ratio was also slightly higher in mothers with 
Pro12Pro genotype at second and third trimester of preg-
nancy, but not at the time of delivery (40 weeks). Besides, 
our investigation reveals that no other immune molecu-
lar and cellular components seems to be altered by the 
Ala allele of rs1808212 PPARG polymorphism in mothers 
at 24 and 34 weeks of pregnancy. However, as newborn 
innate immune system does not seems to be influenced 
by PPARG Pro12Ala polymorphism in cord blood, more 
research is warranted to clarify the role of PPARG on 
immune parameters and their relationship with inflam-
matory response during pregnancy.
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